Faculty Collaboration Database

Pentostatin therapy of T-cell lymphomas with cutaneous manifestations. J Clin Oncol 1999 Oct;17(10):3117-21

Date

10/03/1999

Pubmed ID

10506607

DOI

10.1200/JCO.1999.17.10.3117

Scopus ID

2-s2.0-0032888693 (requires institutional sign-in at Scopus site)   92 Citations

Abstract

PURPOSE: To determine the side effects of and response to pentostatin in patients with T-cell lymphomas with cutaneous manifestations.

PATIENTS AND METHODS: Pentostatin was administered to 28 patients who had relapsed cutaneous T-cell lymphoma or peripheral T-cell lymphoma with prominent cutaneous disease. The starting dose was between 3.75 to 5.0 mg/m(2)/d intravenous for 3 days every 3 weeks.

RESULTS: Of the 24 patients assessable for response, 17 (71%) achieved a partial remission (46%) or complete remission (25%). The patients had a median number of three (range, one to 12) prior therapies. Of the 86 courses of pentostatin given, 39 were administered at doses of 5.0 mg/m(2)/d and 30 at doses of 3. 75 mg/m(2)/d. Dose escalation to 6.25 mg/m(2)/d was possible in only five courses, and toxicity necessitated dose reduction to 2.8 mg/m(2)/d in 12 courses. The most common side effects were granulocytopenia, nausea, and nonneutropenic fever. Most patients developed significant lowering of CD4 counts. Herpes zoster was seen within 1 year after pentostatin in five patients (19%).

CONCLUSION: Pentostatin is an active agent in heavily pretreated T-cell lymphomas with cutaneous manifestations.

Author List

Kurzrock R, Pilat S, Duvic M

Author

Razelle Kurzrock MD Center Associate Director, Professor in the Medicine department at Medical College of Wisconsin

MESH terms used to index this publication - Major topics in bold

Adult
Aged
Antibiotics, Antineoplastic
Dose-Response Relationship, Drug
Female
Humans
Infusions, Intravenous
Lymphoma, T-Cell
Lymphoma, T-Cell, Cutaneous
Male
Middle Aged
Pentostatin
Recurrence
Treatment Outcome